Pharma Drug Pricing Deals
Leavitt announces Thu Regeneron affordability deal (17th firm, Praluent $225 TrumpRx/Medicaid cash global match, free Otarmeni therapy) following Lilly/Merck/Pfizer; ties to psychedelics EO momentum (ibogaine/psilocybin vets PTSD/opioids, FDA rescheduling/$50M research) in 'Golden Age' health strategy.
Sources (2)
Updated Apr 25, 2026